Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals (Q38779980)

6 September 2017

title

Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals (English)

1 reference

6 September 2017

1 reference

1 reference

Caterina Sagnelli

0 references

Evangelista Sagnelli

0 references

Nicola Coppola

1 reference

6 September 2017

Carmine Minichini

series ordinal

1 reference

6 September 2017

Mario Starace

series ordinal

1 reference

6 September 2017

publication date

18 March 2016

1 reference

Journal of Medical Virology

6 September 2017

published in

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

1659-1671

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

6 September 2017

cites work

1 reference

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

21 January 2018

1 reference

Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia

21 January 2018

1 reference

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia

21 January 2018

1 reference

Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.

21 January 2018

1 reference

Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.

21 January 2018

1 reference

Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.

21 January 2018

1 reference

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

21 January 2018

1 reference

HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study

21 January 2018

1 reference

Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK.

21 January 2018

1 reference

Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

21 January 2018

1 reference

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

21 January 2018

1 reference

Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection

21 January 2018

1 reference

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

21 January 2018

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

Simeprevir and sofosbuvir for treatment of hepatitis C infection

21 January 2018

1 reference

Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C

21 January 2018

1 reference

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors

21 January 2018

1 reference

TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism

21 January 2018

1 reference

Role of occult hepatitis B virus infection in chronic hepatitis C

21 January 2018

1 reference

Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals

21 January 2018

1 reference

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance

21 January 2018

1 reference

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study

21 January 2018

1 reference

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

21 January 2018

1 reference

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

21 January 2018

1 reference

Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).

21 January 2018

1 reference

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

21 January 2018

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir

21 January 2018

1 reference

Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded

21 January 2018

1 reference

Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant

21 January 2018

1 reference

Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group

21 January 2018

1 reference

Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy

21 January 2018

1 reference

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance

21 January 2018

1 reference

In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir

21 January 2018

1 reference

Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.

21 January 2018

1 reference

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

21 January 2018

1 reference

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

21 January 2018

1 reference

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin

21 January 2018

1 reference

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

21 January 2018

1 reference

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

21 January 2018

1 reference

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

21 January 2018

1 reference

Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden

21 January 2018

1 reference

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

21 January 2018

1 reference

Hepatitis C virus drug resistance-associated substitutions: State of the art summary

21 January 2018

1 reference

Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir

21 January 2018

1 reference

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

21 January 2018

1 reference

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b

21 January 2018

1 reference

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

21 January 2018

1 reference

Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease

21 January 2018

1 reference

Hepatitis C virus NS5A inhibitors and drug resistance mutations

21 January 2018

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

21 January 2018

1 reference

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

21 January 2018

1 reference

Development and persistence of DAA resistance associated mutations in patients failing HCV treatment

21 January 2018

1 reference

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

21 January 2018

1 reference

Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

21 January 2018

1 reference

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

21 January 2018

1 reference

Hepatitis C Viral NS3-4A Protease Activity Is Enhanced by the NS3 Helicase

21 January 2018

1 reference

Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience

21 January 2018

1 reference

Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients

21 January 2018

1 reference

Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes

21 January 2018

1 reference

Influence of chronic coinfection with hepatitis B and C virus on liver histology.

21 January 2018

1 reference

Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres

21 January 2018

1 reference

Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.

21 January 2018

1 reference

Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment

21 January 2018

1 reference

Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection

21 January 2018

1 reference

Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection

21 January 2018

1 reference

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir

21 January 2018

1 reference

Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study

21 January 2018

1 reference

Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients

21 January 2018

1 reference

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection

21 January 2018

1 reference

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

21 January 2018

1 reference

Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection

21 January 2018

1 reference

Structural analysis of asunaprevir resistance in HCV NS3/4A protease

21 January 2018

1 reference

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

21 January 2018

1 reference

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.

21 January 2018

1 reference

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

21 January 2018

1 reference

Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy

21 January 2018

1 reference

Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

21 January 2018

1 reference

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus

21 January 2018

1 reference

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JMV.24527

1 reference

6 September 2017

1 reference